Patents Assigned to Gruenenthal GmbH
  • Publication number: 20230025025
    Abstract: The present invention relates to compounds according to general formula (I) which act as inhibitors of NaV1.8 and can be used in the treatment of pain.
    Type: Application
    Filed: June 15, 2022
    Publication date: January 26, 2023
    Applicant: GRUENENTHAL GMBH
    Inventors: Sebastian KRUEGER, Sebastian PEIL, Clemens DIALER, Marcel MUELBAIER, Markus WAGENER, Ingo KONETZKI, Nikolay SITNIKOV, Jo ALEN, Martin PETTERSSON
  • Patent number: 11547678
    Abstract: An aqueous pharmaceutical composition containing tapentadol or a physiologically acceptable salt thereof and being adapted for oral administration. The composition has excellent storage stability without relying on the presence of high amounts of preservatives.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: January 10, 2023
    Assignee: Gruenenthal GmbH
    Inventors: Ulrich Reinhold, Marc Schiller, Eva Wulsten, Sabine Karine Katrien Inghelbrecht, Roger Carolus Augusta Embrechts, Ulrich Feil
  • Publication number: 20230000778
    Abstract: A scored tablet comprises Tapentadol or a physiologically acceptable salt thereof embedded in a prolonged release matrix material; wherein the scored tablet provides prolonged release of Tapentadol or the physiologically acceptable salt thereof; wherein the scored tablet has a site of mechanical weakness along which it can be manually broken into two separate halves preferably having essentially the same size, shape and weight; and wherein the in vitro release profile of the scored tablet essentially corresponds to the in vitro release profile of each of the two separate halves. Also disclosed is a process for the preparation of such a scored tablet.
    Type: Application
    Filed: September 14, 2022
    Publication date: January 5, 2023
    Applicant: GRUENENTHAL GMBH
    Inventors: Angelika ELLERMANN, Ulrike BERTRAM, Gerd BARTZ, Udo RUETTGERS
  • Publication number: 20220396578
    Abstract: The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
    Type: Application
    Filed: July 18, 2022
    Publication date: December 15, 2022
    Applicant: GRUENENTHAL GMBH
    Inventors: Jo ALEN, Florian JAKOB, Sebastian KRUEGER, Daniela FRIEBE, Stephanie HENNEN
  • Publication number: 20220372041
    Abstract: The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
    Type: Application
    Filed: July 18, 2022
    Publication date: November 24, 2022
    Applicant: GRUENENTHAL GMBH
    Inventors: Jo ALEN, Florian JAKOB, Sebastian KRUEGER, Philipp BARBIE, Daniela FRIEBE, Stephanie HENNEN
  • Patent number: 11344512
    Abstract: The use of tapentadol for the manufacture of a medicament comprising at least one administration unit A containing dose a of tapentadol and at least one administration unit B containing dose b of tapentadol, where dose a<dose b, for the treatment of pain.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: May 31, 2022
    Assignee: Grünenthal GmbH
    Inventors: Claudia Lange, Ferdinand Rombout
  • Publication number: 20220127264
    Abstract: The invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
    Type: Application
    Filed: January 5, 2022
    Publication date: April 28, 2022
    Applicant: GRUENENTHAL GMBH
    Inventors: Florian JAKOB, Jo Alen, Sebastian Krueger, Markus Schade, Daniela Friebe, Stephanie Hennen
  • Publication number: 20220106294
    Abstract: The invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
    Type: Application
    Filed: December 17, 2021
    Publication date: April 7, 2022
    Applicant: GRUENENTHAL GMBH
    Inventors: Florian JAKOB, Jo ALEN, Sebastian KRUEGER, Philipp BARBIE, Daniela FRIEBE
  • Publication number: 20220106295
    Abstract: The invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
    Type: Application
    Filed: December 17, 2021
    Publication date: April 7, 2022
    Applicant: GRUENENTHAL GMBH
    Inventors: Florian JAKOB, Jo ALEN, Sebastian KRUEGER, Daniela FRIEBE, Stephanie HENNEN
  • Publication number: 20220089573
    Abstract: The invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
    Type: Application
    Filed: January 13, 2020
    Publication date: March 24, 2022
    Applicant: GRÜNENTHAL GMBH
    Inventors: Florian JAKOB, Jo ALEN, Sebastian KRÜGER, Daniela FRIEBE, Stephanie HENNEN, Philipp BARBIE
  • Patent number: 11224576
    Abstract: The present invention relates to a process for the production of abuse-proofed, thermoformed dosage forms containing, apart from one or more active ingredients with potential for abuse and optionally physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: January 18, 2022
    Assignee: GRÜNENTHAL GMBH
    Inventors: Elisabeth Arkenau-Marić, Johannes Bartholomäus
  • Publication number: 20210261492
    Abstract: A hitherto unknown crystalline form of (?)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence.
    Type: Application
    Filed: March 8, 2021
    Publication date: August 26, 2021
    Applicant: Grünenthal GmbH
    Inventors: Andreas FISCHER, Helmut BUSCHMANN, Michael GRUSS, Dagmar LISCHKE
  • Publication number: 20210212967
    Abstract: A method of treating irritable bowel syndrome in a patient in need thereof by administering to said patient a pharmaceutically effective amount of tapentadol.
    Type: Application
    Filed: March 29, 2021
    Publication date: July 15, 2021
    Applicant: Gruenenthal GmbH
    Inventors: Klaus SCHIENE, Petra BLOMS-FUNKE, Thomas CHRISTOPH, Wolfgang SCHROEDER
  • Publication number: 20210214315
    Abstract: The invention relates to 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
    Type: Application
    Filed: March 1, 2021
    Publication date: July 15, 2021
    Applicant: Grünenthal GmbH
    Inventors: Sven Kuehnert, Rene Michael Koenigs, Florian Jakob, Achim Kless, Anita Wegert, Paul Ratcliffe, Ruth Jostock, Thomas Koch, Klaus Linz, Wolfgang Schroeder
  • Publication number: 20210188860
    Abstract: The invention relates to 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
    Type: Application
    Filed: March 1, 2021
    Publication date: June 24, 2021
    Applicant: Grünenthal GmbH
    Inventors: Sven KUEHNERT, Rene KOENIGS, Achim KLESS, Anita WEGERT, Ingo KONETZKI, Paul RATCLIFFE, Ruth JOSTOCK, Thomas KOCH, Klaus LINZ, Wolfgang SCHROEDER
  • Publication number: 20210179592
    Abstract: The invention relates to 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
    Type: Application
    Filed: March 1, 2021
    Publication date: June 17, 2021
    Applicant: Grünenthal GmbH
    Inventors: Sven Kuehnert, Rene Michael Koenigs, Achim Kless, Anita Wegert, Paul Ratcliffe, Ruth Jostock, Thomas Koch, Klaus Linz, Wolfgang Schroeder, Klaus Schiene, Ingo Konetzki
  • Publication number: 20210179627
    Abstract: The invention relates to 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
    Type: Application
    Filed: March 1, 2021
    Publication date: June 17, 2021
    Applicant: Grünenthal GmbH
    Inventors: Sven KUEHNERT, Rene Michael KOENIGS, Florian JAKOB, Achim KLESS, Paul RATCLIFFE, Ruth JOSTOCK, Thomas KOCH, Klaus LINZ, Wolfgang SCHROEDER, Klaus SCHIENE, Anita WEGERT
  • Publication number: 20210179595
    Abstract: The invention relates to 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
    Type: Application
    Filed: March 1, 2021
    Publication date: June 17, 2021
    Applicant: Grünenthal GmbH
    Inventors: Sven KUEHNERT, Rene Michael Koenigs, Achim Kless, Anita Wegert, Paul Ratcliffe, Ruth Jostock, Thomas Koch, Klaus Linz, Wolfgang Schroeder
  • Publication number: 20210163491
    Abstract: The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
    Type: Application
    Filed: February 9, 2021
    Publication date: June 3, 2021
    Applicant: Grünenthal GmbH
    Inventors: Florian JAKOB, Jo ALEN, Simon LUCAS, Tobias CRAAN, Ingo KONETZKI, Achim KLESS, Stefan SCHUNK, Paul RATCLIFFE, Sebastian WACHTEN, Simon CRUWYS
  • Patent number: 11013701
    Abstract: The invention relates to an aqueous pharmaceutical composition for parenteral administration comprising Tapentadol or a physiologically acceptable salt thereof, wherein the concentration of Tapentadol is within the range of from 0.10 to 8.00 mg/mL, based on the weight of Tapentadol free base and based on the total volume of the composition; and wherein the pH value of the composition is buffered and within the range of from 4.0 to 6.0. The invention also relates to a container comprising the pharmaceutical composition and a process for the preparation thereof. The invention also relates to a kit comprising the contained according to the invention in a packaging. The pharmaceutical composition according to the invention is particularly useful for treating pain, especially acute pain, preferably in pediatric patients.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: May 25, 2021
    Assignee: Grünenthal GmbH
    Inventors: Marc Schiller, Carlos van Hemelrijck, Stefanie Straub, Eva Wulsten, Ulrike Bertram, Ulrich Reinhold